| 4.1Economic evaluations of pharmacogenetic and pharmacogenomic screening tests EJJ Berm, M de Looff, B Wilffert, C Boersma, L Annemans, S Vegter, ... Optimizing treatment with psychotropic agents through precision drug therapy …, 2016 | | 2016 |
| A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe S Vegter, K Tolley PloS one 9 (6), e96829, 2014 | 136 | 2014 |
| Aidelsburger P Alici Y Alpert H Angel D Annemans L SA Antoniu, M Arora, A Attema, A Austvoll-Dahlgren, V Backer, S Balu, ... | | |
| Artsen en apothekers miskennen vaak een door ACE-remmers geïnduceerde prikkelhoest, wat de therapietrouw verlaagt S Vegter, P De Boer, KW Van Dijk, S Visser, LTW De Jong-van Den Pharmaceutisch Weekblad 147 (42), 177-180, 2012 | | 2012 |
| Astrological Signs and Health Problems; Demonstrating the Multiple Comparisons Problem S Vegter, JF van Boven, P Pechlivanoglou, MH Rozenbaum, J Stevanovic, ... Value in Health 16 (7), A477, 2013 | | 2013 |
| Choice of first antihypertensive–comparison between the Irish and Dutch setting S Vegter British journal of clinical pharmacology 66 (2), 313, 2008 | 3 | 2008 |
| Clinical and economic impact of non-adherence in COPD: a systematic review JFM van Boven, NH Chavannes, T van der Molen, ... Respiratory medicine 108 (1), 103-113, 2014 | 269 | 2014 |
| Compliance and persistence with antihypertensives in the netherlands; a comparative analysis with specific focus on RAAS intervening agents S Vegter, ST Visser, C Boersma, MJ Postma Value in Health 13 (7), 359, 2010 | | 2010 |
| Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. S Vegter, NH Nguyen, ST Visser, LT de Jong-van den Berg, MJ Postma, ... The American journal of managed care 17 (9), 609, 2011 | 54* | 2011 |
| COPD bespaart kosten J van Boven, E Tommelein, E Mehuys, K Boussery, S Vegter, G Brusselle, ... | | |
| COPD in the working age population: the economic impact on both patients and government JFM Van Boven, S Vegter, T Van Der Molen, MJ Postma COPD: Journal of Chronic Obstructive Pulmonary Disease 10 (6), 629-639, 2013 | 59 | 2013 |
| Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis B Gros, A Galán, E González-Parra, JA Herrero, M Echave, S Vegter, ... Health Economics Review 5, 1-9, 2015 | 8 | 2015 |
| Cost-Effectiveness Analysis Of A Pharmacist-Led Intervention On Improving Inhaler Adherence In Patients With Chronic Obstructive Pulmonary Disease JF Van Boven, E Tommelein, K Boussery, E Mehuys, S Vegter, ... Value in Health 17 (3), A136, 2014 | 1 | 2014 |
| Cost-effectiveness of a pharmaceutical care intervention program to increase bisphosphonates adherence in osteoporosis JFM Van Boven, P Oosterhof, EG Hiddink, AGG Stuurman-Bieze, ... | | |
| Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism S Vegter, A Perna, W Hiddema, P Ruggenenti, G Remuzzi, G Navis, ... Pharmacogenetics and genomics 19 (9), 695, 2009 | 34 | 2009 |
| Cost-Effectiveness of Increasing Statin Adherence for Primary and Secondary Prevention in Community Pharmacies S Vegter, P Oosterhof, JF Van Boven, AGG Stuurman-Bieze, EG Hiddink, ... Value in Health 16 (7), A528, 2013 | | 2013 |
| Cost-Effectiveness of Lanthanum Carbonate in the Treatment of Hyperphosphatemia in Chronic Kidney Disease Before and During Dialysis S Vegter, K Tolley, MS Keith, MJ Postma Value in Health, 2011 | 33 | 2011 |
| Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective S Vegter, K Tolley, MS Keith, CE Lok, SD Soroka, AR Morton Clinical therapeutics 34 (7), 1531-1543, 2012 | 14 | 2012 |
| Costeffectiveness of varicella vaccination programs: an update of the literature MH Rozenbaum, AJ van Hoek, S Vegter, MJ Postma Expert review of vaccines 7 (6), 753-782, 2008 | 70 | 2008 |
| De waarde van therapietrouw S Vegter, E Hiddink, A Stuurman-Bieze, M Postma Pharmaceutische Weekblad Wetenschappelijk Platform 6 (1), 1-18, 2012 | | 2012 |
Mark RozenbaumPfizer在 pfizer.com 的电子邮件经过验证
Mark RozenbaumPfizer在 pfizer.com 的电子邮件经过验证
HH LeUniversity of Cincinnati, University of Groningen在 evidera.com 的电子邮件经过验证